<DOC>
	<DOCNO>NCT03096795</DOCNO>
	<brief_summary>This Phase 1 , randomise , blind , placebo control , study design evaluate safety , tolerability , pharmacokinetics , immunogenicity response single multiple dos MEDI3506 .</brief_summary>
	<brief_title>Safety Tolerability MEDI3506 Healthy Subjects Subjects With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>This Phase 1 , randomise , blind , placebo control , study design evaluate safety , tolerability , pharmacokinetics , immunogenicity response single multiple dos MEDI3506 administer either SC IV route . Part I : Single Ascending Doses Healthy Subjects History Mild Atopy HDM Sensitivity Part II : Multiple Ascending Doses Subjects GOLD I-II COPD</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Inclusion Criteria Part I ( SAD ) 1 . Healthy volunteer age 18 55 year time consent . 2 . Nonsmokers , healthy current smoker , exsmokers permit . 3 . Prebronchodilator FEV1 ≥80 % Predicted . 4 . BMI 19.0 32.0 kg/m2 screening . 5 . Current history mild atopy . 6 . Positive response protocolspecified skin prick test HDM allergen positive HDM specific IgE within 28 day screen . Inclusion Criteria Part II ( MAD ) 1 . Age 40 80 year time screen . 2 . BMI 19.0 35.0 kg/m2 screening . 3 . Normal echocardiographic assessment within year prior randomisation 4 . Documented history COPD postbronchodilator FEV1/FVC &lt; 0.70 postbronchodilator FEV1 ≥50 % predict screening . 5 . Clinically stable free acute exacerbation COPD 8 week prior Day 1 6 . Current smoker tobacco history ≥10 packyears Exclusion Criteria Part I ( SAD ) 1 . Concurrent enrollment another clinical study involve investigational treatment . 2 . Received administration investigational drug participate device trial within month , prior screen ( Visit 1 ) 3 . Subject participate investigator , subinvestigator , study coordinator employee participate site , firstdegree relative aforementioned . 4 . Any active medical psychiatric condition reason , opinion investigator medical monitor , may compromise safety subject study interfere evaluation investigational product reduce subject 's ability participate study . 5 . Any clinically relevant abnormal finding physical examination cardiovascular system include ECG vital sign screen randomization 6 . Abnormal vital sign , 10 minute supine rest Exclusion Criteria Part II ( MAD ) 1 . Participation investigational drug device trial within 30 day 5 halflives , whichever time period longer , prior screen . 2 . Subject participate investigator , subinvestigator , study coordinator , employee participate site , firstdegree relative aforementioned . 3 . Any active medical psychiatric condition reason , opinion investigator , would interfere evaluation investigational product interpretation subject safety study result . This include , limit : 4 . Uncontrolled diabetes 5 . Hypertension screen period 6 . Significant unstable ischaemic heart disease , arrhythmia , cardiomyopathy , heart failure 7 . Clinically significant Aortic stenosis 8 . Pulmonary Arterial Hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MEDI3506</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>